How to analyze the company?LEARNWhat should you know before buying?
Get a brief AI stock analysisSaves ~ 15 minutes of your time

NG

NASDAQ:NGM
Get a brief AI stock analysisSaves ~ 15 minutes of your time

NG

NGM Biopharmaceuticals IncNASDAQ NGM Stock Report

Get a brief AI stock analysis
Saves ~ 15 minutes of your time

Price

Market cap $B

Exchange

XNAS - Nasdaq

FAIR VALUE

Is NGM undervalued compared to its fair value?

The fair value of NGM stock is hidden USD. Relative to the market price of 0 USD NGM Biopharmaceuticals Inc is hidden.

NGM Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The company is headquartered in South San Francisco, California and currently employs 239 full-time employees. The company went IPO on 2019-04-0...[More about valuation]

NGM Biopharmaceuticals Fair Value

hidden
UNLOCK
What is fair value?

Market cap:

0.129 $B

Price:

Fair value:

hidden

Max value:

hidden

Min value:

hidden

P/E:

hidden

EPS:

-0.334

FINANCIALS

NGM Biopharmaceuticals financial for reporting period

Income Statement

0.0002 B N/A

Growth Rates:
1 yearN/A
3 yearsN/A
5 yearsN/A
-0.03 B N/A

Growth Rates:
1 yearN/A
3 yearsN/A
5 yearsN/A
-0.028 B N/A

Growth Rates:
1 yearN/A
3 yearsN/A
5 yearsN/A
Revenue analysis

0.0002 B 100%
-0.03 B -17978%
-0.028 B -16770%

Balance Sheet

0.17 B
0.15 B

Financial Position Analysis

Assets

0.17 B
Current Assets
0.16 B
Total non-current assets
0.012 B

Total current liabilities
0.02 B
Total non-current liabilities
0.0001 B

Cash Flow Statement

-0.023 B N/A

Growth Rates:
1 yearN/A
3 yearsN/A
5 yearsN/A
-0.023 B N/A

Growth Rates:
1 yearN/A
3 yearsN/A
5 yearsN/A

NGM Biopharmaceuticals fundamental analysis for trailing twelve months (TTM)

Profitability Indicators


Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Solvency Indicators


Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Efficiency Indicators

-78 %

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%
-114011 %

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%
-68 %

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Average:
1 yearundefined%
3 yearsundefined%
5 yearsundefined%

Dupont Analysis

Stability Indicators

STOCK ANALYSIS

Is NGM attractive for investment based on fundamental analysis?

NGM stock rating is hidden. NGM Biopharmaceuticals is a hidden by Eyestock methodology.

Get NGM Stock Rating
to complete you analysis
UNLOCK
Learn more about quality score?

Net Profit Margin:

-3 225

Gross Margin:

CFO / Debt ratio:

hidden

Current ratio:

7.18

Debt / Equity ratio:

ROE:

-78

ROIC:

hidden

Stability Ratio (2y):

hidden

Stability Ratio (5y):

hidden

Earnings quality:

hidden

NGM analysis by AI

Eyebot AI analysis

We carefully consider 10 indicators for NGM to calculate the final rating score. Use AI leverage to quickly get the main conclusions before diving into the details

NGM Biopharmaceuticals Inc competitors

LL

LLY

Eli Lilly and Co

Eli Lilly & Co. engages in the discovery, development, manufacture and sale of pharmaceutical products. The company is headquartered in Indianapolis, Indiana and currently employs ...

Discover

NO

NOVO B.CO

Novo Nordisk A/S

Novo Nordisk A/S is a global healthcare company, which engages in the the discovery, development, manufacturing and marketing of pharmaceutical products. The firm is also engaged i...

Discover

JN

JNJ

Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. The company is headquartered in Ne...

Discover

NGM Biopharmaceuticals Inc dividends

NGM dividend metrics

Payout ratio
Dividend yield
Annual dividend
Dividend streak
Average dividend yield over 3 years
Average dividend yield over 5 years

Dividend per share

By years
By payments
1y
3y
5y
All time
This ticker has no dividend history

About NGM stock

About the company NGM Biopharmaceuticals Inc

Market cap $B

0.129

Dividend yield

Shares outstanding

82.0465 B

NGM Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The company is headquartered in South San Francisco, California and currently employs 239 full-time employees. The company went IPO on 2019-04-04. The firm is focused on discovering and developing novel, potentially life-changing medicines based on scientific understanding of key biological pathways underlying cancer, retinal diseases and liver and metabolic diseases. The Company’s robust portfolio of product candidates include NGM707, NGM831, NGM438, NGM120, NGM621, aldafermin and MK-3655. NGM707 is a dual antagonist monoclonal antibody that is designed to improve patient immune responses to tumors by inhibiting both Immunoglobulin-like transcript 2 (ILT2) and Immunoglobulin-like transcript 4 (ILT4). NGM831 is an antagonist antibody that is designed to block the interaction of Immunoglobulin-like transcript 3 (ILT3) with fibronectin, a key component of the tumor stroma, as well as other cognate ligands. NGM438 is an antagonist antibody that is designed to inhibit leukocyte-associated immunoglobulin-like receptor 1 (LAIR1) and promote anti-tumor immune responses.

NGM profile

  • Ticker

    NGM

  • Country

    USA

  • Exchange

    XNAS - Nasdaq

  • Report currency

    USD - US dollar

  • IPO date

    04 April 2019

  • Sector

    Healthсare

  • Industry

    Pharmaceuticals

  • Employees

    239

  • City

    South San Francisco

  • Address

    333 Oyster Point Blvd

  • Cusip

    62921N105